Suppr超能文献

种族差异对乳腺癌新辅助化疗的应用和结局的影响:来自国家癌症数据库的结果。

Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.

机构信息

Brigid K. Killelea, Brandon Hayse, Sarah Mougalian, Nina R. Horowitz, Anees B. Chagpar, Lajos Pusztai, and Donald R. Lannin, Yale University School of Medicine; Brigid K. Killelea, Sarah Mougalian, Nina R. Horowitz, Anees B. Chagpar, Lajos Pusztai, and Donald R. Lannin, Yale Comprehensive Cancer Center; and Vicky Q. Yang and Shi-Yi Wang, Yale University School of Public Health, New Haven, CT.

出版信息

J Clin Oncol. 2015 Dec 20;33(36):4267-76. doi: 10.1200/JCO.2015.63.7801. Epub 2015 Nov 23.

Abstract

PURPOSE

To explore racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer.

METHODS

The National Cancer Data Base was queried to identify women with stage 1 to 3 breast cancer diagnosed in 2010 and 2011. Chemotherapy use and rate of pathologic complete response (pCR) was determined for various racial/ethnic groups.

RESULTS

Of 278,815 patients with known race and ethnicity, 127,417 (46%) received chemotherapy, and of 121,446 where the timing of chemotherapy was known, 27,300 (23%) received neoadjuvant chemotherapy. Chemotherapy, and neoadjuvant chemotherapy in particular, was given more frequently to black, Hispanic, and Asian women than to white women (P < 0.001). This difference was largely explained by more advanced stage, higher grade tumors, and a greater proportion of triple-negative and human epidermal growth factor receptor 2 (HER2)-positive tumors in these women. Of 17,970 patients with known outcome, 5,944 (33%) had a pCR. No differences in response rate for estrogen receptor (ER)/progesterone receptor (PR)-positive tumors were found, but compared with white women, black but not Hispanic or Asian women had a lower rate of pCR for ER/PR-negative, HER2-positive (43% v 54%, P = 0.001) and triple-negative tumors (37% v 43%, P < 0.001). This difference persisted when adjusted for age, clinical T stage, clinical N stage, histology, grade, comorbidity index, facility type, geographic region, insurance status, and census-derived median income and education for the patient's zip code (odds ratio, 0.84; 95% CI, 0.77 to 0.93).

CONCLUSION

Neoadjuvant chemotherapy is given more frequently to black, Hispanic, and Asian women than to white women. Black women have a lower likelihood of pCR for triple-negative and HER2-positive breast cancer. Whether this is due to biologic differences in chemosensitivity or to treatment or socioeconomic differences that could not be adjusted for is unknown.

摘要

目的

探讨新辅助化疗在乳腺癌治疗中的应用和疗效的种族差异。

方法

本研究检索了国家癌症数据库,纳入 2010 年至 2011 年间诊断为 1 期至 3 期乳腺癌的女性患者。确定了不同种族/族裔群体的化疗使用率和病理完全缓解率(pCR)。

结果

在已知种族和民族的 278815 名患者中,有 127417 名(46%)接受了化疗,在已知化疗时间的 121446 名患者中,有 27300 名(23%)接受了新辅助化疗。与白人女性相比,黑人、西班牙裔和亚裔女性接受化疗(尤其是新辅助化疗)的频率更高(P<0.001)。这种差异主要归因于这些女性的肿瘤分期更晚、分级更高,以及三阴性和人表皮生长因子受体 2(HER2)阳性肿瘤的比例更高。在 17970 名已知结局的患者中,有 5944 名(33%)达到了 pCR。ER/PR 阳性肿瘤的缓解率无差异,但与白人女性相比,黑人女性而非西班牙裔或亚裔女性的 ER/PR 阴性、HER2 阳性(43%比 54%,P=0.001)和三阴性肿瘤(37%比 43%,P<0.001)的 pCR 率更低。当调整年龄、临床 T 分期、临床 N 分期、组织学、分级、合并症指数、医疗机构类型、地理区域、保险状况以及患者邮政编码的人口统计中位数收入和教育程度等因素后,这种差异仍然存在(比值比,0.84;95%置信区间,0.77 至 0.93)。

结论

新辅助化疗在黑人、西班牙裔和亚裔女性中比在白人女性中更为常用。黑人女性的三阴性和 HER2 阳性乳腺癌患者 pCR 率较低。这是否是由于化疗敏感性的生物学差异,还是由于无法调整的治疗或社会经济差异导致的,尚不清楚。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验